Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, examine the evolving treatment landscape for geographic atrophy, reviewing long-term extension data for complement inhibitors, anatomic versus functional outcomes, practical approaches to patient selection and inflammation monitoring, and the real-world challenges of cost, access, and setting appropriate expectations for disease progression.
Anaya is assistant professor of ophthalmology at Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland. He has no relevant financial disclosures.
Abbey is in practice at Texas Retina Associates in Dallas, Texas, and director of clinical research. He is a speaker and consultant for Apellis Pharmaceuticals, Inc and Astellas Pharma Inc.